Clinical trial
Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced…
NCT00004925 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00004925 |
|---|---|
| Title | Liposomal Doxorubicin and Trastuzumab in Treating Women With Locally Advanced, Inflammatory, or Metastatic Breast Cancer |
| Official title | Phase I/II Study of TLC D-99 Plus Herceptin as First or Second Line Therapy for Patients With Locally Advanced Inflammatory or Metastatic Breast Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug |
| Interventions | trastuzumab, pegylated liposomal doxorubicin hydrochloride |
| Start date | Aug 1, 1999 |
| Primary completion | Aug 1, 2003 |
| Completion | Aug 1, 2003 |
| First posted | May 14, 2003 |
| Last update posted | Jun 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: